Qivitan LC 75 mg Intramammary Ointment for Lactating Cows

Land: Verenigd Koninkrijk

Taal: Engels

Bron: VMD (Veterinary Medicines Directorate)

Werkstoffen:

Cefquinome

Beschikbaar vanaf:

Livisto Int'l S.L.

ATC-code:

QJ51DE90

INN (Algemene Internationale Benaming):

Cefquinome

farmaceutische vorm:

Intramammary ointment

Prescription-type:

POM-V - Prescription Only Medicine – Veterinarian

Therapeutische categorie:

Cattle

Therapeutisch gebied:

Antimicrobial intramammary

Autorisatie-status:

Authorized

Autorisatie datum:

2018-06-07

Productkenmerken

Unlimited Renewal: October 2022
AN: 01917/2022
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Qivitan LC 75 mg intramammary ointment for lactating cows
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each prefilled syringe of 8 g contains:
ACTIVE SUBSTANCE:
Cefquinome
75 mg
(as cefquinome sulfate 88.92 mg)
EXCIPIENTS:
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Intramammary ointment
White to slightly yellow, oily viscous homogeneous ointment.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle (lactating cows).
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of clinical mastitis in the lactating cow caused by
the following
cefquinome-sensitive organisms: _Streptococcus uberis, Streptococcus _
_dysgalactiae, Staphylococcus aureus_ and_ Escherichia coli_.
4.3
CONTRAINDICATIONS
Do not use in known cases of hypersensitivity to cephalosporin
antibiotics, other
ß-lactam antibiotics or to any of the excipients.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5
SPECIAL PRECAUTIONS FOR USE
i.
Special precautions for use in animals
Unlimited Renewal: October 2022
AN: 01917/2022
Page 2 of 5
The product should be reserved for the treatment of clinical
conditions which
have responded poorly or are expected to respond poorly to other
classes of
antimicrobials or narrow spectrum β-lactam antimicrobials.
Use of the product should be based on susceptibility testing of the
bacteria
isolated from the animal. If it is not possible, therapy should be
based on local
(regional, farm level) epidemiological information about
susceptibility of the target
bacteria.
Official, national and regional antimicrobial policies should be taken
into account
when the product is used.
Use of the product deviating from the instructions given in the SPC
may increase
the
prevalence
of
bacteria
resistant
to
cefquinome
and
may
decrease
the
effectiveness of treatment with cephalosporins due to the potential
for cross-
resistance.
The feeding to calves of milk